Shares of CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) have received a consensus rating of “Buy” from the nine analysts that are presently covering the company, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $63.88.
Several equities research analysts have commented on the stock. Roth Mkm initiated coverage on shares of CG Oncology in a report on Tuesday, August 27th. They issued a “buy” rating and a $65.00 price target on the stock. Royal Bank of Canada began coverage on CG Oncology in a research note on Monday, September 23rd. They issued an “outperform” rating and a $66.00 target price on the stock. Bank of America reiterated a “buy” rating and set a $65.00 price target on shares of CG Oncology in a research report on Tuesday, October 8th. HC Wainwright restated a “buy” rating and issued a $75.00 price objective on shares of CG Oncology in a research report on Tuesday. Finally, UBS Group began coverage on shares of CG Oncology in a report on Thursday, October 24th. They set a “buy” rating and a $60.00 target price for the company.
Get Our Latest Analysis on CGON
CG Oncology Stock Up 1.0 %
CG Oncology (NASDAQ:CGON – Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.06. The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.30 million. Research analysts anticipate that CG Oncology will post -1.45 EPS for the current year.
Insider Activity
In related news, Director Hong Fang Song sold 650,455 shares of the company’s stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $35.36, for a total transaction of $23,000,088.80. Following the completion of the transaction, the director now owns 586,982 shares in the company, valued at $20,755,683.52. This represents a 52.56 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Hedge Funds Weigh In On CG Oncology
A number of hedge funds have recently made changes to their positions in the company. Decheng Capital LLC purchased a new stake in shares of CG Oncology during the first quarter worth approximately $239,642,000. Vanguard Group Inc. purchased a new stake in shares of CG Oncology during the first quarter worth $97,678,000. BVF Inc. IL acquired a new stake in shares of CG Oncology in the first quarter valued at about $82,716,000. Yu Fan purchased a new position in shares of CG Oncology in the second quarter worth about $49,828,000. Finally, Janus Henderson Group PLC acquired a new position in CG Oncology during the first quarter worth about $66,757,000. Institutional investors and hedge funds own 26.56% of the company’s stock.
About CG Oncology
CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.
Featured Articles
- Five stocks we like better than CG Oncology
- EV Stocks and How to Profit from Them
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- Why Are Stock Sectors Important to Successful Investing?
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- Learn Technical Analysis Skills to Master the Stock Market
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.